Nanovibronix Retained Earnings (Accumulated Deficit) 2014-2024 | NAOV

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Nanovibronix retained earnings (accumulated deficit) from 2014 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Nanovibronix Retained Earnings (Accumulated Deficit) 2014-2024 | NAOV

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Related Stocks
Company Name	Market Cap
Thermo Fisher Scientific (TMO)	$233.2B
Intuitive Surgical (ISRG)	$171.7B
Alcon (ALC)	$47.9B
IQVIA Holdings (IQV)	$43.7B
IDEXX Laboratories (IDXX)	$42.2B
Edwards Lifesciences (EW)	$40.5B
DexCom (DXCM)	$27.6B
STERIS (STE)	$23.8B
SONOVA HOLDING (SONVY)	$21.2B
Waters (WAT)	$19.5B
Hologic (HOLX)	$19B
Sysmex ADR (SSMXY)	$12.6B
Fresenius Medical Care AG KGaA (FMS)	$12.3B
Teleflex (TFX)	$11.4B
Globus Medical (GMED)	$9.4B
Penumbra (PEN)	$7.3B
Glaukos (GKOS)	$6.7B
Masimo (MASI)	$6.1B
TransMedics (TMDX)	$5.2B
Integer Holdings (ITGR)	$4.2B
PROCEPT BioRobotics (PRCT)	$4.1B
Tandem Diabetes Care (TNDM)	$2.8B
LivaNova (LIVN)	$2.8B
Veracyte (VCYT)	$2.6B
Inari Medical (NARI)	$2.6B
Elekta AB (EKTAY)	$2.5B
Nihon Kohden (NHNKY)	$2.5B
RxSight (RXST)	$2.1B
Integra LifeSciences Holdings (IART)	$1.3B
Pulse Biosciences (PLSE)	$1.2B